Renovacor
Renovacor is a pre-revenue clinical-stage biopharmaceutical company developing gene therapy-based treatments for cardiovascular and central nervous system diseases, formerly traded on NYSE under RCOR following a 2021 SPAC merger.
- Company typePublic
- Founded2013
- HeadquartersPhiladelphia, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Renovacor firmographics
Firmographics- Name
- Renovacor
- Legal name
- Renovacor, Inc.
- Website
- https://renovacor.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Ipo
- Headcount range
- 11–50 employees
- Short description
- Renovacor is a pre-revenue clinical-stage biopharmaceutical company developing gene therapy-based treatments for cardiovascular and central nervous system diseases, formerly traded on NYSE under RCOR following a 2021 SPAC merger.
- Ownership category
- akta.pro rank
Renovacor industry classification
Industry- Product category
- Biopharmaceutical Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurology/CNS Gene Therapies (HLAAACAH)
- akta.pro secondary industry
- Lentiviral Vector Gene Therapy Developers (HLAAACAB)
Keywords
Where Renovacor is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Markets served
Renovacor business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Others
Renovacor product offering
Product offeringCore offering
Renovacor is a biopharmaceutical company that develops gene therapy-based treatments aimed at cardiovascular disease and central nervous system disorders. The company leverages an AI-driven drug discovery capability to support the development of its pipeline of targeted gene therapies addressing unmet medical needs in these therapeutic areas.
Differentiator
Problem solved
Functional benefit
Products and services
- Cardiovascular and CNS Gene Therapy Pipeline
Companies that use Renovacor
Customer profileSegments1 record
Ideal customer profiles1 record
Renovacor technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Renovacor partnerships and signals
Strategic signalScale indicators3 records
Renovacor competitors and assessment
Company assessmentDirect peers
- Lexeo Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments for both cardiac diseases and CNS/brain disorders — directly mirroring Renovacor's cardiovascular + CNS focus and target indications.
- Tenaya Therapeutics: Genetic medicines company focused on cardiac gene therapies for heart failure and cardiomyopathy — the closest direct competitor in cardiovascular gene therapy with comparable platform and indication strategy.
Broad incumbents
- Asklepios BioPharmaceutical (AskBio): Acquired by Bayer, AskBio develops AAV-based gene therapies including cardiac indications (e.g., Pompe disease, heart failure). A larger, well-capitalized incumbent with overlapping cardiovascular gene therapy programs.
- BioMarin Pharmaceutical: Large biopharmaceutical company with an established gene therapy franchise (Roctavian for hemophilia A) and broader rare disease pipeline — broad incumbent with gene therapy capabilities relevant to Renovacor's modality.
- Pfizer: Large pharmaceutical company with significant cardiovascular and gene therapy investments (e.g., Beqvez for hemophilia B, in-house AAV programs) — broad incumbent that competes for talent, partnerships, and market in cardiovascular gene therapy.
Emerging players
- uniQure: Clinical-stage gene therapy company developing AAV-based treatments, with established expertise in cardiovascular (e.g., heart failure) and CNS indications — overlapping platform technology and therapeutic focus with Renovacor.
- Rocket Pharmaceuticals: Clinical-stage gene therapy company targeting rare diseases including cardiac (e.g., Danon disease) — comparable platform-based AAV/lentiviral gene therapy approach in overlapping cardiovascular indications.
- Solid Biosciences: Gene therapy company developing AAV-based treatments for neuromuscular and cardiac diseases — comparable platform technology with shared focus on cardiac indications such as Duchenne muscular dystrophy cardiomyopathy.
- bluebird bio: Gene therapy company developing lentiviral and AAV-based treatments for severe genetic diseases — comparable modality with experience in managing complex gene therapy development and commercial operations.
Others
- Regenxbio: Gene therapy platform company developing proprietary AAV technologies and a pipeline spanning ophthalmology, CNS, and metabolic diseases — comparable enabling AAV platform technology used by Renovacor.
Market position
Customer concentration
Renovacor social profiles
Digital presenceRenovacor financial estimates
Financial estimateRevenue estimate
Valuation estimate
Renovacor leadership team
Management profileNumber of profiles
Profiles5 records
Renovacor funding detail
Funding detailFunding overview
Funding rounds2 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Renovacor M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Renovacor
What does Renovacor do?
Renovacor is a biopharmaceutical company that develops gene therapy-based treatments aimed at cardiovascular disease and central nervous system disorders. The company leverages an AI-driven drug discovery capability to support the development of its pipeline of targeted gene therapies addressing unmet medical needs in these therapeutic areas.
Is Renovacor a public or private company?
Renovacor is a public company. It is classified as unknown and is currently ipo.
When was Renovacor founded?
Renovacor was founded in 2013. It employs 11 to 50 people.
Where is Renovacor based?
Renovacor is headquartered in Philadelphia, United States, in the North America region.
Who are Renovacor's main competitors?
Direct peers on record are Lexeo Therapeutics and Tenaya Therapeutics. Broad incumbents are Asklepios BioPharmaceutical (AskBio), BioMarin Pharmaceutical and Pfizer. Emerging players are uniQure, Rocket Pharmaceuticals, Solid Biosciences and bluebird bio. Regenxbio is listed as an others.
Does Renovacor have an API?
No public API is recorded for Renovacor.
What industry is Renovacor in?
Renovacor's product category is Biopharmaceutical Gene Therapy. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies, with a secondary code of HLAAACAB, Lentiviral Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 8731.